Skip to search formSkip to main contentSkip to account menu

GW 1516

Known as: GW-1516, GW1516 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Peroxisome proliferator-activated receptors (PPARs) have been intensively studied as drug targets to treat type 2 diabetes, lipid… 
2013
2013
.......................................................................................5 Introduction… 
2012
2012
The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the… 
2012
2012
Peroxisome proliferator-activated receptor-δ (PPARδ) agonists are the drug candidates with potential performance-enhancing… 
2012
2012
Objective: The peroxisome proliferator-activated receptor (PPAR) delta has been implicated in systemic lipid homeostasis and… 
2010
2010
AbstractSince January 2009, the list of prohibited substances and methods of doping as established by the World Anti-Doping… 
2007
2007
In this specification, by administering PPARδ agonist to a subject (e.g., GW1516) in combination with exercise program, it…